These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 10783342)

  • 21. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study.
    Humaidan P; Bungum M; Bungum L; Yding Andersen C
    Reprod Biomed Online; 2004 Jun; 8(6):635-43. PubMed ID: 15169576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone.
    Cabrera RA; Stadtmauer L; Mayer JF; Gibbons WE; Oehninger S
    Fertil Steril; 2005 Jan; 83(1):42-8. PubMed ID: 15652885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction.
    Balasch J; Creus M; Fábregues F; Civico S; Carmona F; Puerto B; Casamitjana R; Vanrell JA
    J Assist Reprod Genet; 2001 May; 18(5):250-6. PubMed ID: 11464575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates.
    Lahoud R; Al-Jefout M; Tyler J; Ryan J; Driscoll G
    Hum Reprod; 2006 Oct; 21(10):2645-9. PubMed ID: 16785261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.
    Ragni G; Vegetti W; Baroni E; Colombo M; Arnoldi M; Lombroso G; Crosignani PG
    Hum Reprod; 2001 Nov; 16(11):2258-62. PubMed ID: 11679500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
    Mitchell R; Buckler HM; Matson P; Lieberman B; Burger HG; Hilton B; Horne G; Dyson M; Robertson WR
    Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ovarian stimulation with human and recombinant gonadotropin - comparison of in vitro fertilization efficiency with use of time-lapse monitoring.
    Wdowiak A; Bojar I
    Reprod Health; 2015 Dec; 12():113. PubMed ID: 26667662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of gonadotropins in follicular development and their use in ovulation induction protocols for assisted reproduction.
    Zafeiriou S; Loutradis D; Michalas S
    Eur J Contracept Reprod Health Care; 2000 Jun; 5(2):157-67. PubMed ID: 10943580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer.
    Merviel P; Antoine JM; Mathieu E; Millot F; Mandelbaum J; Uzan S
    Fertil Steril; 2004 Jul; 82(1):119-25. PubMed ID: 15236999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Luteinizing hormone response to gonadotrophin-releasing hormone in normal women undergoing ovulation induction with urinary or recombinant follicle stimulating hormone.
    Messinis IE; Milingos S; Zikopoulos K; Hasiotis G; Seferiadis K; Lolis D
    Hum Reprod; 1998 Sep; 13(9):2415-20. PubMed ID: 9806260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outlook: who needs LH in ovarian stimulation?
    Alviggi C; Clarizia R; Mollo A; Ranieri A; De Placido G
    Reprod Biomed Online; 2006 May; 12(5):599-607. PubMed ID: 16790105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH.
    Levi-Setti PE; Cavagna M; Bulletti C
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):212-6. PubMed ID: 16377062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles.
    Albano C; Smitz J; Tournaye H; Riethmüller-Winzen H; Van Steirteghem A; Devroey P
    Hum Reprod; 1999 Jun; 14(6):1426-30. PubMed ID: 10357952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists.
    Felberbaum R; Diedrich K
    Hum Reprod; 1999 Sep; 14 Suppl 1():207-21. PubMed ID: 10573035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of low day 3 luteinizing hormone levels on in vitro fertilization treatment outcome.
    Noci I; Maggi M; Fuzzi B; Biagiotti R; Ricci F; Marchionni M
    Gynecol Endocrinol; 2000 Oct; 14(5):321-6. PubMed ID: 11109971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
    König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
    Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
    Reyes FI; Winter JS; Faiman C
    Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant luteinizing hormone in ovarian hyperstimulation after stimulation failure in normogonadotropic women.
    Laml T; Obruca A; Fischl F; Huber JC
    Gynecol Endocrinol; 1999 Apr; 13(2):98-103. PubMed ID: 10399054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.